# Daiichi Sankyo clinical trials: 322 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 322 trials with Daiichi Sankyo as lead sponsor, 35 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Daiichi Sankyo: 322 rows for $16.10, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/daiichi-sankyo

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 322
- Recruiting or not yet: 35
- Read on: November 19, 2026

## Trials

The 25 newest of 322, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07890714 | A Study of Dato-DXd in Participants With Solid Tumors \[TROPION-PanTumor04 (TP04)\] | Daiichi Sankyo | Phase 1/2 | Recruiting | Urothelial Cancer, Non-small Cell Lung Cancer | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890714) |
| October 15, 2026 | NCT07874555 | A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban | Daiichi Sankyo | Observational | Completed | Atrial Fibrillation, Renal Dysfunction | 8,265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874555) |
| October 7, 2026 | NCT07863284 | Medical Access Program for DS-9606a (DS-9606) in Patients With Advanced Testicular Germ Cell Tumors | Daiichi Sankyo | Not applicable | Available | Advanced Testicular Germ Cell Tumors, Metastatic Testicular Germ Cell Tumors | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863284) |
| October 7, 2026 | NCT07862465 | Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell... | Daiichi Sankyo | Not applicable | Available | Peripheral T-cell Lymphomas, Adult T-cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, Refractory Nodal... | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862465) |
| August 28, 2026 | NCT07791732 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent... | Daiichi Sankyo | Phase 3 | Not yet recruiting | Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791732) |
| July 31, 2026 | NCT07739966 | A Study of DS-3939a in Participants With Solid Tumors | Daiichi Sankyo | Phase 1/2 | Recruiting | Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739966) |
| July 14, 2026 | NCT07701941 | A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low... | Daiichi Sankyo | Phase 1/2 | Recruiting | Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701941) |
| July 6, 2026 | NCT07683754 | T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment... | Daiichi Sankyo | Phase 3 | Recruiting | Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683754) |
| July 2, 2026 | NCT07681882 | First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors | Daiichi Sankyo | Phase 1 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681882) |
| April 17, 2026 | NCT07535359 | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer | Daiichi Sankyo | Not applicable | No longer available | SCLC, Extensive-stage Small Cell Lung Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535359) |
| March 16, 2026 | NCT07474649 | A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events | Daiichi Sankyo | Phase 3 | Recruiting | Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07474649) |
| December 8, 2025 | NCT07268625 | Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin | Daiichi Sankyo | Phase 1 | Completed | Healthy Subjects | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268625) |
| November 24, 2025 | NCT07244341 | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | Daiichi Sankyo | Phase 1 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244341) |
| November 19, 2025 | NCT07235189 | A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin | Daiichi Sankyo | Phase 1 | Completed | Healthy Subjects | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235189) |
| October 24, 2025 | NCT07220616 | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | Daiichi Sankyo | Phase 1/2 | Recruiting | Hematological Malignancies, B-cell Non-Hodgkin Lymphoma | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220616) |
| October 3, 2025 | NCT07206472 | A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed... | Daiichi Sankyo | Observational | Recruiting | Primary Hypercholesterolaemia, Mixed Dyslipidemia | 2,120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206472) |
| October 1, 2025 | NCT07201545 | Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin | Daiichi Sankyo | Phase 1 | Completed | Healthy Subjects | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07201545) |
| September 24, 2025 | NCT07189403 | A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | Daiichi Sankyo | Phase 1 | Recruiting | Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189403) |
| September 19, 2025 | NCT07182591 | A Study of DS5361b in Participants With Advanced Solid Tumors | Daiichi Sankyo | Phase 1 | Recruiting | Advanced Solid Tumor | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07182591) |
| September 19, 2025 | NCT07182383 | Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin | Daiichi Sankyo | Phase 1 | Completed | Healthy Subjects | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07182383) |
| September 8, 2025 | NCT07159126 | A Study of DS3610a in Participants With Advanced Solid Tumor | Daiichi Sankyo | Phase 1 | Recruiting | Solid Tumors, Metastatic Solid Tumors | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07159126) |
| August 19, 2025 | NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally... | Daiichi Sankyo | Phase 2/3 | Recruiting | Urothelial Cancer, Bladder Cancer | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07129993) |
| July 29, 2025 | NCT07092254 | Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer | Daiichi Sankyo | Observational | Active not recruiting | Triple Negative Breast Cancer | 760 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07092254) |
| June 15, 2025 | NCT07022483 | A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant... | Daiichi Sankyo | Phase 3 | Recruiting | Endometrial Cancer | 710 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07022483) |
| June 11, 2025 | NCT07015697 | A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors | Daiichi Sankyo | Phase 1 | Recruiting | Recurrent or Metastatic Solid Tumors | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07015697) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 3 |
| Phase 1 | 95 |
| Phase 1/2 | 21 |
| Phase 2 | 68 |
| Phase 2/3 | 5 |
| Phase 3 | 64 |
| Phase 4 | 25 |
| Not applicable | 8 |
| Observational | 33 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 224 |
| Recruiting | 34 |
| Terminated | 30 |
| Active not recruiting | 22 |
| Withdrawn | 5 |
| No longer available | 3 |
| Available | 2 |
| Approved for marketing | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 29 |
| Diabetes Mellitus, Type 2 | 22 |
| Hypertension | 18 |
| Neoplasm Metastasis | 16 |
| Leukemia, Myeloid, Acute | 15 |
| Breast Neoplasms | 14 |
| Recurrence | 13 |
| Colorectal Neoplasms | 11 |
| Neoplasms | 11 |
| Ovarian Neoplasms | 10 |
| Atrial Fibrillation | 10 |
| Essential Hypertension | 9 |
| Venous Thromboembolism | 9 |
| Hypercholesterolemia | 8 |
| Lung Neoplasms | 7 |
| Leukemia | 7 |
| Diabetes Mellitus | 6 |
| Venous Thrombosis | 6 |
| Pulmonary Embolism | 6 |
| Lymphoma | 5 |
| Sarcoma | 5 |
| Stomach Neoplasms | 5 |
| Fibromyalgia | 5 |
| Endometrial Neoplasms | 5 |
| Pancreatic Neoplasms | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Social media agencies in the United States](https://specstream.ai/data/businesses/social-media-agencies/united-states)
- [Air duct cleaning companies in the United States](https://specstream.ai/data/businesses/air-duct-cleaning-companies/united-states)
- [Certification bodies in the United States](https://specstream.ai/data/businesses/certification-bodies/united-states)
- [Fence contractors in the United States](https://specstream.ai/data/businesses/fence-contractors/united-states)
- [Landscape architecture firms in the United States](https://specstream.ai/data/businesses/landscape-architecture-firms/united-states)
